pharma · Metastatic Melanoma · Unresectable Melanoma · IOVA
Iovance Biotherapeutics
Iovance Biotherapeutics B.V.
Iovance Biotherapeutics is a pharma organization headquartered in San Carlos, USA. It trades on NYSE under ticker IOVA. Primary therapeutic focus areas include Metastatic Melanoma, Unresectable Melanoma, Metastatic Non-S
Company details
- Status
- Public
- HQ
- 825 Industrial Rd, Suite 400, San Carlos, California 94070, US
- Founded
- 2007
- Employees
- 916
- Programs
- 36
- Drugs
- 26
- Patents
- 94
Quick answer
Iovance Biotherapeutics is a pharma organization headquartered in San Carlos, USA. It trades on NYSE under ticker IOVA. Primary therapeutic focus areas include Metastatic Melanoma, Unresectable Melanoma, Metastatic Non-Small-Cell Lung Cancer, Recurrent, metastatic, or persistent Cervical Carcinoma, Neoplasm. NovaPharmaNews links 36 clinical program(s), 1 drug profile(s), and 94 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (21), phase 1 (12), phase 3 (2).
Company snapshot
Iovance Biotherapeutics (NASDAQ: IOVA) aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promi
- 1 approved product(s) across US/EU regulatory metadata.
- 36 active pipeline program(s) linked via ClinicalTrials.gov.
- 94 US patent(s) indexed to this assignee profile.
Public regulatory, clinical, patent, and corporate records for Iovance Biotherapeutics. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- approval
FDA Clears Iovance IL-12 TIL Trial, Signaling New Frontier in Solid Tumor Therapy
- trial_data
Biotech Movers: Moderna, Iovance, ALHC, and Summit Therapeutics in Focus
Recent coverage
FDA Clears Iovance IL-12 TIL Trial, Signaling New Frontier in Solid Tumor Therapy
The FDA has cleared Iovance Biotherapeutics' Investigational New Drug application for IOV-5001, a novel IL-12 tethered TIL therapy designed for advanced solid tumors. This clearance allows for the initiation of a Phase 1/2 clinical trial, potentially expanding treatment options for patients with difficult-to-treat indications.
Biotech Movers: Moderna, Iovance, ALHC, and Summit Therapeutics in Focus
Biotech stocks showed mixed performance as Moderna advanced its Ebola vaccine efforts and Summit Therapeutics saw a surge on Phase 3 data. Meanwhile, Alignment Healthcare faced a downgrade, and Iovance Biotherapeutics remains a subject of analyst debate.
Top assets
Lead pipeline drugs
- Marketed / approved
- approved
- approved
- Marketed / approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 2
- Phase 2
Momentum
Proprietary activity score for Iovance Biotherapeutics.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for Iovance Biotherapeutics.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Iovance Biotherapeutics?
-
Is Iovance Biotherapeutics publicly traded?
-
What drugs does Iovance Biotherapeutics develop or market?
-
What are the latest developments for Iovance Biotherapeutics?
-
What therapeutic areas does Iovance Biotherapeutics focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.